Carmen Gonzalez, MD
Pulmonary Disease · Fishersville, VANPI 1245294610
Payments from drug & device makers
Across 246 payments — averaging $47.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$3K
- Medical Device Business Services, Inc.$3K
- AstraZeneca$1K
- Sanofi$602
- Johnson & Johnson$384
- Regeneron Healthcare Solutions, Inc.$336
- plus $3K from 32 others
What the payments were for
- Travel & lodging$3,43730%
- Food & beverage$5,59148%
- Education$2,59822%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 6 | $3,301 |
| Medical Device Business Services, Inc. | 11 | $2,840 |
| AstraZeneca(2 entities) | 38 | $1,187 |
| Sanofi | 20 | $602 |
| Johnson & Johnson | 5 | $384 |
| Regeneron Healthcare Solutions, Inc. | 15 | $336 |
| GSK | 17 | $287 |
| Verona Pharma, Inc. | 19 | $278 |
| Mylan Specialty L.p. | 15 | $237 |
| Insmed, Inc. | 10 | $217 |
| Grifols USA, LLC | 7 | $191 |
| Philips North America LLC | 8 | $187 |
| Galvanize Therapeutics, Inc | 2 | $170 |
| United Therapeutics Corporation | 7 | $157 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $152 |
| Electromed, Inc. | 8 | $152 |
| Boehringer Ingelheim | 8 | $132 |
| Merck | 6 | $106 |
| Amgen | 4 | $82 |
| Avadel CNS Pharmaceuticals, LLC | 3 | $80 |
| ANI Pharmaceuticals, Inc. | 3 | $69 |
| Viatris Specialty LLC | 3 | $59 |
| AbbVie(2 entities) | 3 | $53 |
| Genentech USA, Inc. | 3 | $49 |
| Harmony Biosciences LLC | 2 | $43 |
| La Jolla Pharmaceutical Company | 2 | $38 |
| Jazz Pharmaceuticals Inc. | 1 | $29 |
| Shionogi Inc | 1 | $26 |
| Vifor Pharma, Inc. | 1 | $25 |
| Baxter Healthcare | 1 | $24 |
| Novartis | 1 | $21 |
| Lilly USA, LLC | 1 | $20 |
| Pfizer | 1 | $18 |
| Circassia Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $15 |
| Tactile Systems Technology Inc | 1 | $14 |
| Phadia US Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,254
- MONARCH$2,765
- BREZTRI$411
- AIRSUPRA$310
- TEZSPIRE$284
- Monarch Platform$143
- ALIYA SYSTEM$130
- SYMBICORT$101
How this compares
$11,626 in reported general payments places this provider in the 75th percentile of 317 pulmonary disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 528 | $380,736 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 300 | $202,690 |
| Dupixent PenDupilumab | 26 | $94,542 |
| TezspireTezepelumab-Ekko | 15 | $64,512 |
| NucalaMepolizumab | 12 | $44,375 |
| Breo ElliptaFluticasone/Vilanterol | 93 | $43,305 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 32 | $21,861 |
| Spiriva RespimatTiotropium Bromide | 26 | $18,085 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 19 | $11,933 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 323 | $7,641 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 33 | $7,286 |
| SymbicortBudesonide/Formoterol Fumarate | 23 | $6,814 |
| Qvar RedihalerBeclomethasone Dipropionate | 24 | $6,732 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 11 | $5,655 |
| Arnuity ElliptaFluticasone Furoate | 26 | $5,504 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $287 | $491,125691 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort, Bevespi Aerosphere | $1,187 | $279,672349 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $132 | $39,94658 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $14 | $6,73224 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 317 pulmonary disease providers in Virginia.
Other pulmonary disease in Fishersville
- Timothy SciallaFishersville$99K
- Steven NathanFalls Church$2.5M
- Shilpa JohriRichmond$1.7M
- Omar MinaiHopewell$1.3M
- Vijay SubramaniamWilliamsburg$1.3M
- Rabih HalabiFalls Church$604K
- Patricia SimeRichmond$572K
- Apostolos PerelasRichmond$567K
- Hannah MannemCharlottesville$326K
- Ray ShepherdRichmond$303K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.